According to recent research published in ‘Alzheimer's & Dementia’, delays in entering the rapid eye movement (REM) sleep ...

The European Commission has requested its medicines regulator to consider safety information on Eisai and Biogen's ...

One recent analysis found that, over the course of three years, people taking semaglutide (the compound in Ozempic and the weight loss drug Wegovy) were about 40 to 70 percent less likely to be ...

Taking too long to enter the phase of sleep in which we dream may be an early sign of Alzheimer's disease. This is the ...

Groundbreaking study uncovers the crucial link between REM sleep patterns and Alzheimer's disease, providing new insights for ...

New research uncovers how declining protein clearance mechanisms with age lead to Alzheimer’s, Parkinson’s, and other ...

Delays in dreaming might be an early warning sign of Alzheimer's disease. People who take significantly longer to enter the ...

SaveHealth provides an overview of Alzheimer's disease, including treatment and coping mechanisms for those with the disease ...

European Union regulators will review new information relating to the safety of Eisai Co.’s and Biogen Inc.’s medicine for ...

Taking longer to enter the dream phase can disrupt the ability to consolidate memories and interfere with emotion regulation.

The reassessment of Leqembi’s safety data follows the agency’s previous recommendation of the drug for use in the EU.

Funded by a $3 million National Institutes of Health grant, the two universities plan to study the relationship between two ...